Malabsorption Syndromes

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2025-05-23
EMA Authorised: Revestive (teduglutide) — Takeda Pharmaceuticals International AG Ireland
The European Medicines Agency authorised Revestive (teduglutide) for malabsorption syndromes. The decision date was 22 May 2025.